SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fisher SB, Patel SH, Bagci P, et al. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer. 2013;119:445453.
  • 2
    Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:39283935.
  • 3
    Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187195.
  • 4
    Fujita H, Ohuchida K, Mizumoto K, et al. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia. 2010;12:807817.
  • 5
    Marechal R, Bachet J, Mackey JR, et al. Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression [abstract]. J Clin Oncol. 2011;29(15 suppl). Abstract 4024.
  • Amir Avan, MSc

  • Mina Maftouh, MSc

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands

  • Department of New Sciences and Technology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

  • Elisa Giovannetti, MD, PhD

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands